<code id='621352262E'></code><style id='621352262E'></style>
    • <acronym id='621352262E'></acronym>
      <center id='621352262E'><center id='621352262E'><tfoot id='621352262E'></tfoot></center><abbr id='621352262E'><dir id='621352262E'><tfoot id='621352262E'></tfoot><noframes id='621352262E'>

    • <optgroup id='621352262E'><strike id='621352262E'><sup id='621352262E'></sup></strike><code id='621352262E'></code></optgroup>
        1. <b id='621352262E'><label id='621352262E'><select id='621352262E'><dt id='621352262E'><span id='621352262E'></span></dt></select></label></b><u id='621352262E'></u>
          <i id='621352262E'><strike id='621352262E'><tt id='621352262E'><pre id='621352262E'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:explore    - browse:868
          Adobe

          Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

          In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

          advertisement

          The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge